3
Announcements
Trials
Browse
Landscape
Status
Completed
261
Terminated
88
Active not recruiting
66
Recruiting
55
Withdrawn
21
Unknown
14
Not yet recruiting
9
No longer available
3
Suspended
2
Approved for marketing
1
Sponsor Class
INDUSTRY
3
Study Type
Expanded_access
3
Sponsor
Cancer Type
Dermatologic
2
Thoracic
1
Conditions
Melanoma
2
Squamous Non-Small Cell Lung Cancer
1
Interventions
nilotinib
4
dabrafenib
4
trametinib
3
regorafenib
3
midostaurin
3
elotuzumab
3
Nivolumab
3
tazemetostat
2
talimogene laherparepvec
2
ceritinib
2
TIC10 compound
2
Suspensions
2
Prednisone
2
Powders
2
Panobinostat
2
Melphalan
2
Lenalidomide
2
Ipilimumab
2
Everolimus
2
Dexamethasone
2
Crizotinib
2
Bortezomib
2
Bevacizumab
2
Axitinib
2
zanubrutinib
1
zanidatamab
1
venetoclax
1
veliparib
1
tucatinib
1
talquetamab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
No longer available
×
INDUSTRY
×
Nivolumab
×
Clear all
NCT06590480
2025-12-18
RPL-EAP-001
Replimune, Inc.
No longer available
NCT02475382
2020-11-27
CheckMate 169
Bristol-Myers Squibb
No longer available
NCT02186249
2017-02-08
CheckMate218
Bristol-Myers Squibb
No longer available